OvaScience's Augment fertility treatment available in Japan
US fertility specialist OvaScience (Nasdaq: OVAS) says its Augment fertility treatment is now being offered in Japan through a preceptorship program at IVF JAPAN, one of the most prestigious fertility clinic systems in that country.
The initiation of the preceptorship program, in which patients will receive the Augment treatment, follows approval from the Japan Society of Obstetrics and Gynecology (JSOG).
“The introduction of the Augment treatment in Japan represents an important milestone for patients,” said Michelle Dipp, chief executive of OvaScience, adding: “We look forward to working to expand the availability of the Augment treatment to women who experience poor egg health and are in need of new fertility treatment options.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze